Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · IEX Real-Time Price · USD
2.210
0.00 (0.00%)
At close: May 6, 2024, 3:57 PM
2.250
+0.040 (1.81%)
After-hours: May 6, 2024, 5:53 PM EDT

Barinthus Biotherapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Cash & Equivalents
142.09194.39214.0543.2711.43
Cash & Cash Equivalents
142.09194.39214.0543.2711.43
Cash Growth
-26.90%-9.19%394.74%278.46%-
Receivables
05.850.020.520.99
Other Current Assets
14.8212.8112.694.123.83
Total Current Assets
156.91213.04226.7747.916.25
Property, Plant & Equipment
19.415.719.092.772.79
Goodwill and Intangibles
37.3240.4844.0600
Other Long-Term Assets
0.880.980.800
Total Long-Term Assets
57.657.1653.952.772.79
Total Assets
214.51270.21280.7250.6719.04
Accounts Payable
1.63.752.424.673.89
Deferred Revenue
000.180.250.27
Current Debt
1.790.430.680.190.17
Other Current Liabilities
9.218.067.882.541.42
Total Current Liabilities
12.612.2411.167.645.75
Long-Term Debt
11.198.346.5446.171.61
Other Long-Term Liabilities
3.726.4210.4600
Total Long-Term Liabilities
14.9114.761746.171.61
Total Liabilities
27.512728.1553.817.36
Total Debt
12.988.777.2246.361.78
Debt Growth
47.91%21.48%-84.42%2507.98%-
Retained Earnings
-176.59-103.24-108.59-57.72-37.89
Comprehensive Income
-23.32-33.46-8.49-1.24-0.47
Shareholders' Equity
186.78242.9252.13-36.91-22.45
Net Cash / Debt
129.11185.61206.83-3.19.65
Net Cash / Debt Growth
-30.44%-10.26%---
Net Cash Per Share
3.364.867.99-0.390.41
Working Capital
144.31200.8215.6140.2610.5
Book Value Per Share
4.876.529.74-4.67-0.96
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).